The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The new facility is expected to significantly improve access to high-quality medical services for patients across Gujarat and neighbouring regions
AI-enabled learning platform to enhance clinical quality, patient outcomes, and staff engagement across Eastern India network
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery
These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Subscribe To Our Newsletter & Stay Updated
